About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: N/A
- Symbol: NYSEAMERICAN:ATNM
- Previous Symbol: AMEX:ATNM
- CUSIP: N/A
- Web: www.actiniumpharmaceuticals.com
- Trailing EPS: ($0.47)
- Return on Equity: -260.21%
- Return on Assets: -181.24%
- Outstanding Shares: 80,030,000
Frequently Asked Questions for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."
How were Actinium Pharmaceuticals' earnings last quarter?
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) released its quarterly earnings data on Monday, March, 16th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.
Where is Actinium Pharmaceuticals' stock going? Where will Actinium Pharmaceuticals' stock price be in 2017?
3 analysts have issued twelve-month price objectives for Actinium Pharmaceuticals' shares. Their predictions range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' share price to reach $5.00 in the next twelve months. View Analyst Ratings for Actinium Pharmaceuticals.
Are investors shorting Actinium Pharmaceuticals?
Actinium Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,904,751 shares, an increase of 73.4% from the October 13th total of 1,098,379 shares. Based on an average trading volume of 1,484,562 shares, the days-to-cover ratio is currently 1.3 days. Currently, 2.5% of the company's shares are sold short.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include Verona Pharma Plc (VRP), Trevena (TRVN), Zafgen (ZFGN), Gemphire Therapeutics (GEMP), ProQR Therapeutics N.V. (PRQR), Ampio Pharmaceuticals (AMPE), Motif Bio plc (MTFB), Affimed N.V. (AFMD), Synthetic Biologics (SYN), MEI Pharma (MEIP), Nexvet Biopharma plc (NVET), Viking Therapeutics (VKTX), ADMA Biologics (ADMA), Aeglea BioTherapeutics (AGLE), Lipocine (LPCN), Ergomed PLC (ERGO), Flex Pharma (FLKS) and Applied Genetic Technologies Corporation (AGTC).
Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the folowing people:
- Sandesh Seth, Executive Chairman of the Board, Chief Executive Officer (Age 53)
- Steve O'Loughlin, Principal Financial and Accounting Officer
- Nitya G. Ray Ph.D., Executive Vice President, Head - Product Development, Manufacturing and Supply Chain (Age 63)
- Steven Price, Vice President - Clinical and Commercial Strategy
- Mark Stanley Berger, Chief Medical Officer
- C. David Nicholson Ph.D., Independent Director (Age 62)
- Ajit S. Shetty Ph.D., Independent Director
- Richard I. Steinhart CPA, Independent Director (Age 59)
How do I buy Actinium Pharmaceuticals stock?
Shares of Actinium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Actinium Pharmaceuticals' stock price today?
One share of Actinium Pharmaceuticals stock can currently be purchased for approximately $0.67.
How big of a company is Actinium Pharmaceuticals?
Actinium Pharmaceuticals has a market capitalization of $52.02 million.
How can I contact Actinium Pharmaceuticals?
Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.
MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$5.00|
Consensus Price Target History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
Analysts' Ratings History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
(Data available from 11/20/2015 forward)
|11/14/2017||Maxim Group||Set Price Target||Buy||$3.00|
|10/23/2017||HC Wainwright||Reiterated Rating||Buy||$6.00|
|10/23/2017||Roth Capital||Reiterated Rating||Buy||$6.00|
|11/2/2016||FBR & Co||Reiterated Rating||Buy||$9.00|
Earnings History and Estimates Chart for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
Earnings History by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/2/2017||Nitya G Ray||Insider||Buy||10,000||$0.75||$7,500.00|| |
|8/2/2017||Sandesh Seth||CEO||Buy||33,333||$0.75||$24,999.75|| |
|6/15/2017||Sandesh Seth||Chairman||Buy||7,500||$1.16||$8,700.00|| |
|6/15/2017||Steve O'loughlin||Insider||Buy||3,500||$1.17||$4,095.00|| |
|12/30/2016||Sandesh Seth||Insider||Buy||5,000||$0.88||$4,400.00|| |
|12/12/2016||Sandesh Seth||Insider||Buy||5,000||$0.98||$4,900.00|| |
|8/31/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||192,927||$1.83||$353,056.41|| |
|8/29/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||50,000||$1.71||$85,500.00|| |
|8/16/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||9,468||$1.72||$16,284.96|| |
|7/12/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||3,100||$1.80||$5,580.00|| |
|7/11/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||21,990||$1.80||$39,582.00|| |
|7/6/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||20,840||$1.81||$37,720.40|| |
|7/1/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||148,100||$1.81||$268,061.00|| |
|6/15/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||33,619||$1.90||$63,876.10|| |
|6/2/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||17,790||$2.01||$35,757.90|| |
|6/1/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||169,450||$1.97||$333,816.50|| |
|5/26/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||40,068||$1.92||$76,930.56|| |
|5/25/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||36,400||$1.90||$69,160.00|| |
|4/26/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||52,577||$2.04||$107,257.08|| |
|4/21/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||196,497||$2.03||$398,888.91|| |
|4/18/2016||Sandesh Seth||Chairman||Buy||15,000||$1.99||$29,850.00|| |
|4/15/2016||Sergio Traversa||Director||Buy||3,000||$2.02||$6,060.00|| |
|4/14/2016||Kaushik J Dave||CEO||Buy||10,000||$2.02||$20,200.00|| |
|4/14/2016||Richard I Steinhart||Director||Buy||2,500||$2.01||$5,025.00|| |
Latest Headlines for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Chart for Monday, November, 20, 2017